{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:40:23Z","timestamp":1765546823744,"version":"3.40.5"},"reference-count":77,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.clml.2021.11.014","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T03:56:43Z","timestamp":1637899003000},"page":"347-355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["SOHO State of the Art Updates and Next Questions: Waldenstr\u00f6m Macroglobulinemia - 2021 Update on Management and Future Directions"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8596-7058","authenticated-orcid":false,"given":"Sheeba K.","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clml.2021.11.014_bib0001","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom\u2019s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2021.11.014_bib0002","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.clml.2021.11.014_bib0003","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/bjh.13264","article-title":"Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database","volume":"169","author":"Castillo","year":"2015","journal-title":"Br J Haematol"},{"issue":"5\u20136","key":"10.1016\/j.clml.2021.11.014_bib0004","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000360992","article-title":"Outcome disparities among ethnic subgroups of Waldenstrom\u2019s macroglobulinemia: a population-based study","volume":"86","author":"Ailawadhi","year":"2014","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.clml.2021.11.014_bib0005","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clml.2021.11.014_bib0006","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.mayocp.2018.02.011","article-title":"Fifty-Year Incidence of Waldenstrom Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review","volume":"93","author":"Kyle","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"15","key":"10.1016\/j.clml.2021.11.014_bib0007","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1002\/cncr.26627","article-title":"Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study","volume":"118","author":"Wang","year":"2012","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.clml.2021.11.014_bib0008","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/jnci\/djq043","article-title":"Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia","volume":"102","author":"Kristinsson","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.clml.2021.11.014_bib0009","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/annonc\/mdj111","article-title":"Characterization of familial Waldenstrom\u2019s macroglobulinemia","volume":"17","author":"Treon","year":"2006","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.clml.2021.11.014_bib0010","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2008-06-162768","article-title":"Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma\/Waldenstrom macroglobulinemia patients: a population-based study in Sweden","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2021.11.014_bib0011","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1182\/blood-2015-01-622068","article-title":"Population-based study on the impact of the familial form of Waldenstrom macroglobulinemia on overall survival","volume":"125","author":"Steingrimsson","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2021.11.014_bib0012","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3324\/haematol.2012.070458","article-title":"Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom\u2019s macroglobulinemia","volume":"98","author":"Nguyen-Khac","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2021.11.014_bib0013","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.2006.06389.x","article-title":"6q deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis","volume":"136","author":"Ocio","year":"2007","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.clml.2021.11.014_bib0014","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1182\/blood-2012-06-436329","article-title":"MYD88 L265P mutation in Waldenstrom macroglobulinemia","volume":"121","author":"Poulain","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2021.11.014_bib0015","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/leu.2013.62","article-title":"MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom\u2019s macroglobulinemia","volume":"27","author":"Jimenez","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2021.11.014_bib0016","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","article-title":"MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction","volume":"121","author":"Xu","year":"2013","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2021.11.014_bib0017","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1182\/blood-2012-09-457101","article-title":"Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom\u2019s macroglobulinemia and related lymphoid neoplasms","volume":"121","author":"Varettoni","year":"2013","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2021.11.014_bib0018","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2021.11.014_bib0019","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjh.15560","article-title":"TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstrom macroglobulinaemia","volume":"184","author":"Gustine","year":"2019","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.clml.2021.11.014_bib0020","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1182\/blood-2011-10-384768","article-title":"Progression in smoldering Waldenstrom macroglobulinemia: long-term results","volume":"119","author":"Kyle","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2021.11.014_bib0021","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.beha.2016.08.014","article-title":"Prognostic factors and indications for treatment of Waldenstrom's Macroglobulinemia","volume":"29","author":"Kyle","year":"2016","journal-title":"Best Pract Res Clin Haematol"},{"issue":"23","key":"10.1016\/j.clml.2021.11.014_bib0022","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1182\/blood.2019000725","article-title":"How I treat Waldenstrom macroglobulinemia","volume":"134","author":"Dimopoulos","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.11.014_bib0023","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood.V118.21.3692.3692","article-title":"Incidence of peripheral neuropathy in Waldenstr\u00f6m Macroglobulinemia patients at diagnosis","volume":"118","author":"Paba-Prada","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2021.11.014_bib0024","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/jnnp.2005.071175","article-title":"Peripheral neuropathies in Waldenstrom\u2019s macroglobulinaemia","volume":"77","author":"Levine","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.clml.2021.11.014_bib0025","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/bjh.14492","article-title":"Investigation and management of IgM and Waldenstrom-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel","volume":"176","author":"D\u2019Sa","year":"2017","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2021.11.014_bib0026","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3324\/haematol.2016.147728","article-title":"Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome","volume":"102","author":"Minnema","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2021.11.014_bib0027","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3816\/CLM.2009.n.026","article-title":"Waldenstrom's macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia","volume":"9","author":"Stone","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2021.11.014_bib0028","article-title":"Acquired Von Willebrand Disease in Patients with Waldenstr\u00f6m Macroglobulinemia","volume":"130","author":"Castillo","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.11.014_bib0029","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood.V97.6.1885","article-title":"Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy","volume":"97","author":"Choufani","year":"2001","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2021.11.014_bib0030","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood-2018-06-846816","article-title":"Acute hyperviscosity: syndromes and management","volume":"132","author":"Gertz","year":"2018","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2021.11.014_bib0031","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","article-title":"International prognostic scoring system for Waldenstrom macroglobulinemia","volume":"113","author":"Morel","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2021.11.014_bib0032","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.leukres.2010.04.005","article-title":"Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom\u2019s macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)","volume":"34","author":"Kastritis","year":"2010","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.clml.2021.11.014_bib0033","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1080\/10428190410001714043","article-title":"Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98)","volume":"45","author":"Gertz","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2021.11.014_bib0034","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/annonc\/mdi022","article-title":"Extended rituximab therapy in Waldenstrom\u2019s macroglobulinemia","volume":"16","author":"Treon","year":"2005","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clml.2021.11.014_bib0035","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(16)30166-1","article-title":"Once-weekly ofatumumab in untreated or relapsed Waldenstrom\u2019s macroglobulinaemia: an open-label, single-arm, phase 2 study","volume":"4","author":"Furman","year":"2017","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.clml.2021.11.014_bib0036","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00277-018-3311-z","article-title":"Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia","volume":"97","author":"Paludo","year":"2018","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.clml.2021.11.014_bib0037","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","article-title":"Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom\u2019s macroglobulinemia","volume":"124","author":"Treon","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.clml.2021.11.014_bib0038","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1200\/JCO.2007.10.9926","article-title":"Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide","volume":"25","author":"Dimopoulos","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2021.11.014_bib0039","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","article-title":"Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study","volume":"126","author":"Kastritis","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2021.11.014_bib0040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.15148","article-title":"Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenstrom macroglobulinaemia","volume":"181","author":"Castillo","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.11.014_bib0041","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2019-121909","volume":"134","author":"Rummel","year":"2019","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2021.11.014_bib0042","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.2009.23.6315","article-title":"Rituximab and subcutaneous 2-chloro-2\u2032-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study","volume":"28","author":"Laszlo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2021.11.014_bib0043","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/sonc.2003.50070","article-title":"2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom\u2019s macroglobulinemia","volume":"30","author":"Weber","year":"2003","journal-title":"Semin Oncol"},{"year":"2007","series-title":"Primary 2-CDA and Cyclophosphamide +\/- Rituximab for Symptomatic Waldenstrom\u2019s Macroglobulinemia (WM). in XIth International Myeloma Workshop","author":"Thomas","key":"10.1016\/j.clml.2021.11.014_bib0044"},{"issue":"2","key":"10.1016\/j.clml.2021.11.014_bib0045","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/cncr.26303","article-title":"Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease","volume":"118","author":"Tedeschi","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.11.014_bib0046","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood.V112.11.3065.3065","article-title":"Incidence of Transformation to Large Cell Lymphoma and to Second Malignancies in Symptomatic Patients with Waldenstrom\u2019s Macroglobulinemia (WM) Treated with Cladribine (2-CdA) Combination Induction Therapy","volume":"112","author":"Rakkhit","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.11.014_bib0047","series-title":"5th International Workshop on Waldenstr\u00f6m\u2019s Macroglobulinemia","article-title":"Success Rates of Autologous Stem Cell Collection in Patients with Waldenstr\u00f6m\u2019s Macroglobulinemia","author":"Thomas","year":"2008"},{"issue":"2","key":"10.1016\/j.clml.2021.11.014_bib0048","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1200\/JCO.2007.15.1530","article-title":"Increased incidence of transformation and myelodysplasia\/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs","volume":"27","author":"Leleu","year":"2009","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clml.2021.11.014_bib0049","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1182\/bloodadvances.2020001963","article-title":"Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstrom macroglobulinemia: long-term follow-up","volume":"4","author":"Castillo","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.11.014_bib0050","first-page":"2772","article-title":"Long-Term Follow-up of a Prospective Clinical Trial of Carfilzomib, Rituximab and Dexamethasone (CaRD) in Waldenstrom\u2019s Macroglobulinemia","volume":"130","author":"Meid","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.11.014_bib0051","doi-asserted-by":"crossref","first-page":"8065","DOI":"10.1200\/JCO.2016.34.15_suppl.8065","article-title":"Long-term follow-up of exceptional responders on the phase II trial of weekly bortezomib and rituximab in untreated and relapsed patients with waldenstrom\u2019s macroglobulinemia","volume":"34","author":"Cappuccio","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2021.11.014_bib0052","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/ajh.21788","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia","volume":"85","author":"Ghobrial","year":"2010","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.clml.2021.11.014_bib0053","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","article-title":"Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)","volume":"122","author":"Dimopoulos","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2021.11.014_bib0054","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMc1506192","article-title":"MYD88 Mutations and Response to Ibrutinib in Waldenstrom's Macroglobulinemia","volume":"373","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.clml.2021.11.014_bib0055","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom\u2019s Macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.11.014_bib0056","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/blood-2018-99-111178","article-title":"Ibrutinib Treatment in Waldenstr\u00f6m\u2019s Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATETM Study","volume":"132","author":"Buske","year":"2018","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.clml.2021.11.014_bib0057","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","article-title":"Ibrutinib Monotherapy in Symptomatic, Treatment-Naive Patients With Waldenstrom Macroglobulinemia","volume":"36","author":"Treon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2021.11.014_bib0058","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.3324\/haematol.2017.186908","article-title":"Ibrutinib withdrawal symptoms in patients with Waldenstrom macroglobulinemia","volume":"103","author":"Castillo","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.11.014_bib0059","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1182\/blood-2018-99-112325","article-title":"Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia","volume":"132","author":"Castillo","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2021.11.014_bib0060","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"18","key":"10.1016\/j.clml.2021.11.014_bib0061","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2021.11.014_bib0062","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bbmt.2007.01.083","article-title":"Autologous stem cell transplantation as part of first-line treatment of Waldenstrom's macroglobulinemia","volume":"13","author":"Dreger","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"10.1016\/j.clml.2021.11.014_bib0063","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1200\/JCO.2009.24.4905","article-title":"High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2021.11.014_bib0064","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s00277-019-03734-7","article-title":"Outcomes of autologous stem cell transplantation in Waldenstrom\u2019s macroglobulinemia","volume":"98","author":"Saini","year":"2019","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.clml.2021.11.014_bib0065","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.bbmt.2006.04.010","article-title":"Autologous or allogeneic stem cell transplantation in patients with Waldenstrom\u2019s macroglobulinemia","volume":"12","author":"Anagnostopoulos","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.clml.2021.11.014_bib0066","doi-asserted-by":"crossref","first-page":"e694","DOI":"10.1016\/j.clml.2020.05.021","article-title":"Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenstrom Macroglobulinemia: A Systematic Review and Meta-analysis","volume":"20","author":"Parrondo","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"33","key":"10.1016\/j.clml.2021.11.014_bib0067","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2009.27.3607","article-title":"Allogeneic stem-cell transplantation in patients with Waldenstrom macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2021.11.014_bib0068","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3324\/haematol.2009.017814","article-title":"Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom\u2019s macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"95","author":"Garnier","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2021.11.014_bib0069","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bbmt.2016.10.010","article-title":"Allogeneic Transplantation for Relapsed Waldenstrom Macroglobulinemia and Lymphoplasmacytic Lymphoma","volume":"23","author":"Cornell","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"10.1016\/j.clml.2021.11.014_bib0070","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/blood-2017-01-761726","article-title":"Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia","volume":"129","author":"Xu","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.11.014_bib0071","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-137237","article-title":"LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenstr\u00f6m\u2019s Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1\/2 BRUIN Study","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.11.014_bib0072","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1200\/JCO.2021.39.15_suppl.7502","article-title":"First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed\/refractory (R\/R) CLL and other hematologic malignancies (HMs)","volume":"39","author":"Ailawadhi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.11.014_bib0073","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1182\/blood-2019-128564","article-title":"Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Non-Hodgkin\u2019s Lymphoma and Chronic Lymphocytic Leukemia","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.11.014_bib0074","first-page":"5089","article-title":"Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenstr\u00f6m macroglobulinemia","volume":"4","author":"Castillo","year":"2020","journal-title":"Blood Advances"},{"key":"10.1016\/j.clml.2021.11.014_bib0075","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1200\/JCO.2021.39.15_suppl.7561","article-title":"Treatment free remission (TFR) and overall response rate (ORR) results in patients with relapsed\/refractory Waldenstrom\u2019s macroglobulinemia (WM) treated with CLR 131","volume":"39","author":"Ailawadhi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2021.11.014_bib0076","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/10428194.2019.1665668","article-title":"Chimeric antigen receptor T cells for treatment of transformed Waldenstrom macroglobulinemia","volume":"61","author":"Bansal","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.11.014_bib0077","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood-2018-99-117737","article-title":"Phase I clinical trial of CD19-Targeted 19-28Z\/4-1BBL \"Armored\" Car T Cells in patients with relapsed or refractory NHL and CLL including richter transformation","volume":"132","author":"Batlevi","year":"2018","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021024472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021024472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T13:58:55Z","timestamp":1682949535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021024472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":77,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2152265021024472"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.11.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions: Waldenstr\u00f6m Macroglobulinemia - 2021 Update on Management and Future Directions","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}